Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
NCT03405194 · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic · NA · withdrawn · last registry update 2020-03-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Haiti gained access to dolutegravir as first-line ART, so we cancelled the study before any patient was enrolled (we didn't want SOC group to receive EFV)” | – | Registry record, Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP3A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-11Results posted on the registry: University of Colorado, Denver, TDF with a boosted protease inhibitor + TAF with a boosted protease inhibitor (NCT03126370)
- 2021-01-14Also stopped (withdrawn): Azienda Ospedaliero-Universitaria di Parma, Oxytocin + Standard of Care (NCT04386447)
- 2020-12-04Phase 3 first posted: Chelsea and Westminster NHS Foundation Trust, Biktarvy + Symtuza (NCT04653194)
- 2020-11-06Also stopped (terminated): Giovanni Di Perri, emtricitabine, darunavir/cobicistat, maraviroc (NCT03163277)
- 2020-08-27Results posted on the registry: Gilead Sciences, B/F/TAF + NRTIs (NCT03631732)
- 2020-07-17Phase 3 first posted: University of Rome Tor Vergata, liposomal lactoferrin + SOC therapy (NCT04475120)
- 2020-07-07Also stopped (terminated): Janssen Pharmaceutica N.V., Belgium, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC + Darunavir (NCT04236453)
- 2020-02-05Phase 3 first posted: Shanghai Public Health Clinical Center, Darunavir and Cobicistat (NCT04252274)
- 2020-01-07Results posted on the registry: Janssen Scientific Affairs, LLC, DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC (NCT03227861)
- 2019-12-05Results posted on the registry: Gilead Sciences, B/F/TAF (NCT03405935)
- 2019-11-26Results posted on the registry: Medicines for Malaria Venture, Single oral dose of 800 mg OZ439 + Single oral dose of 400 mg OZ439 (NCT04069221)
- 2019-11-04Results posted on the registry: Gilead Sciences, E/C/F/TAF (NCT02616029)
- 2019-10-31Results posted on the registry: University of California, San Diego, Stribild + Genvoya (NCT02251236)
- 2019-09-17Results posted on the registry: Emory University, Truvada + Genvoya (NCT02985996)
- 2019-05-29Results posted on the registry: GlaxoSmithKline, GSK2838232 + Cobicistat (NCT03045861)
- 2019-04-26Also stopped (withdrawn): Henry M. Jackson Foundation for the Advancement of Military Medicine, Genvoya 150Mg-150Mg-200Mg-10Mg Tablet (NCT03877536)
- 2019-04-03Results posted on the registry: Merck Sharp & Dohme LLC, Doravirine, Tenofovir, Lamivudine + Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor (NCT02397096)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision